| Age, median and range in years |
66 (48-91) |
68 (53-94) |
67 (48-94) |
| Race |
|
|
|
| Black or African American |
1 (6) |
1 (8) |
2 (7) |
| Native American/Alaska Native |
1 (6) |
0 (0) |
1 (3) |
| Native Hawaiian or Other Pacific Islander |
1 (6) |
0 (0) |
1 (3) |
| White non-Hispanic |
14 (82) |
12 (92) |
26 (87) |
| Karnofsky performance status (KPS) |
|
|
|
| ≤80 |
8 (47) |
7 (54) |
15 (50) |
| 90-100 |
9 (53) |
5 (38) |
14 (47) |
| Missing |
0 (0) |
1 (8) |
1 (3) |
| Gleason sum |
|
|
|
| 6 |
2 (12) |
3 (23) |
5 (17) |
| 7 |
4 (24) |
3 (23) |
7 (23) |
| 8-10 |
11 (65) |
6 (46) |
17 (57) |
| Missing |
0 (0) |
1 (8) |
1 (3) |
| Prior docetaxel |
|
|
|
| No |
6 (35) |
4 (31) |
10 (33) |
| Yes |
11 (65) |
9 (69) |
20 (67) |
| #Prior systemic therapies |
|
|
|
| 0-2 |
4 (24) |
1 (8) |
5 (17) |
| 3-5 |
5 (29) |
3 (23) |
8 (27) |
| 6-8 |
6 (35) |
7 (54) |
13 (43) |
| ≥9 |
2 (12) |
2 (15) |
4 (13) |
| Metastatic disease |
|
|
|
| Bone ± node, no visceral metastases |
10 (59) |
8 (62) |
18 (60) |
| Visceral metastases |
7 (41) |
5 (48) |
12 (40) |
| Opiate use |
9 (53) |
3 (23) |
12 (40) |
|
PSA, median (ng/dl) |
82 (0.05-650) |
49 (4.6-5317) |
70 (0.05-5317) |
| Median circulating tumour cells |
4 (0-112) |
21 (1-60) |
15 (0-112) |
| (cells per 7.5 mL), n = 22 evaluable |
|
|
|
|
Alkaline phosphatase (IU/L) |
87 (25-493) |
88 (26-943) |
88 (25-943) |
|
Haemoglobin, g/dl |
11.2 (9.2-14.5) |
11.5 (9.5-13.7) |
11.3 (9.2-14.5) |
| Lactate dehydrogenase (LDH) |
198 (132-1273) |
189 (147-2000) |
195 (132-2000) |
